[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 52 of about 52
1. Xu Q, Yuan X, Tunici P, Liu G, Fan X, Xu M, Hu J, Hwang JY, Farkas DL, Black KL, Yu JS: Isolation of tumour stem-like cells from benign tumours. Br J Cancer; 2009 Jul 21;101(2):303-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation of tumour stem-like cells from benign tumours.
  • BACKGROUND: Cancerous stem-like cells (CSCs) have been implicated as cancer-initiating cells in a range of malignant tumours.
  • We set out to test whether tumour stem-like cells can be identified from benign tumours.
  • Characterisation of tumour stem-like cells in vitro was performed using self-renewal assays, stem cell-associated marker expression analysis, differentiation, and stimulated hormone production assays.
  • The tumour-initiating capability of these tumour stem-like cells was tested in serial brain tumour transplantation experiments using SCID mice.
  • RESULTS: In this study, we isolated sphere-forming, self-renewable, and multipotent stem-like cells from pituitary adenomas, which are benign tumours.
  • We found that pituitary adenoma stem-like cells (PASCs), compared with their differentiated daughter cells, expressed increased levels of stem cell-associated gene products, antiapoptotic proteins, and pituitary progenitor cell markers.
  • CONCLUSION: This study for the first time indicates that stem-like cells are present in benign tumours.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Sep;75 Suppl 3:iii47-52 [15316045.001]
  • [Cites] Curr Opin Genet Dev. 2004 Oct;14(5):567-74 [15380249.001]
  • [Cites] Mol Endocrinol. 1994 Jul;8(7):878-85 [7527122.001]
  • [Cites] Annu Rev Med. 1996;47:95-106 [8712806.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] J Endocrinol. 2005 Jan;184(1):41-50 [15642781.001]
  • [Cites] Mol Endocrinol. 2005 Apr;19(4):964-71 [15637144.001]
  • [Cites] Endocrinology. 2005 May;146(5):2376-87 [15677762.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] J Neurosci Res. 2005 May 15;80(4):456-66 [15795928.001]
  • [Cites] Exp Cell Res. 2005 Aug 1;308(1):166-76 [15916758.001]
  • [Cites] J Clin Pharmacol. 2005 Aug;45(8):872-7 [16027397.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):650-3 [18385740.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Breast Cancer Res. 2008;10(2):105 [18423071.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Neuroscience. 2008 Jun 23;154(2):541-50 [18462887.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] Stem Cells. 2008 Dec;26(12):3018-26 [18787206.001]
  • [Cites] Endocrinology. 2005 Sep;146(9):3985-98 [15932930.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Glia. 2006 Feb;53(3):294-303 [16265670.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Jan;4(1):63-72 [16562373.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Genes Dev. 2006 Oct 1;20(19):2739-53 [17015435.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2382-90 [16857898.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Neuroendocrinology. 2007;85(2):110-30 [17337880.001]
  • [Cites] Physiol Rev. 2007 Jul;87(3):933-63 [17615393.001]
  • [Cites] Science. 2007 Jul 20;317(5836):337 [17641192.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1109-23 [18083101.001]
  • [Cites] Dev Neurosci. 2000;22(1-2):139-53 [10657706.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1180-7 [10720059.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):892-9 [11557786.001]
  • [Cites] Clin Neurosurg. 2001;48:306-19 [11692649.001]
  • [Cites] Science. 2002 Mar 22;295(5563):2231-5 [11910101.001]
  • [Cites] Ultrastruct Pathol. 2002 Jul-Aug;26(4):219-28 [12227947.001]
  • [Cites] Exp Neurol. 2002 Dec;178(2):288-93 [12504887.001]
  • [Cites] Pituitary. 2002;5(2):89-98 [12675506.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):285-95 [15057288.001]
  • (PMID = 19568241.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS048959-04; United States / NINDS NIH HHS / NS / R01 NS048959; United States / NINDS NIH HHS / NS / NS048959; United States / NINDS NIH HHS / NS / R01 NS048959-04; United States / NINDS NIH HHS / NS / R56 NS048959; United States / NINDS NIH HHS / NS / R21 NS048879-02; United States / NINDS NIH HHS / NS / NS048879-02; United States / NINDS NIH HHS / NS / R21 NS048879; United States / NINDS NIH HHS / NS / NS048879
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hypothalamic Hormones; 0 / Pituitary Hormones
  • [Other-IDs] NLM/ PMC2720199
  •  go-up   go-down


2. Lim SD, Stallcup W, Lefkove B, Govindarajan B, Au KS, Northrup H, Lang D, Fisher DE, Patel A, Amin MB, Arbiser JL: Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas neoplasms of stem cells? Mol Med; 2007 Mar-Apr;13(3-4):160-5
Cellosaurus - a cell line knowledge resource. culture/stock collections - UMB1949 (CVCL_C471) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas neoplasms of stem cells?
  • Angiomyolipomas are benign tumors of the kidney which express phenotypes of smooth muscle, fat, and melanocytes.
  • These tumors appear with increased frequency in the autosomal dominant disorder tuberous sclerosis and are the leading cause of morbidity in adults with tuberous sclerosis.
  • While benign, these tumors are capable of provoking life threatening hemorrhage and replacement of the kidney parenchyma, resulting in renal failure.
  • The histogenesis of these tumors is currently unclear, although currently, we believe these tumors arise from "perivascular epithelioid cells" of which no normal counterpart has been convincingly demonstrated.
  • Recently, stem cell precursors have been recognized that can give rise to smooth muscle and melanocytes.
  • These precursors have been shown to express the neural stem cell marker NG2 and L1.
  • Immunohistochemistry of human angiomyolipoma specimens revealed uniform staining of tumor cells, while renal cell carcinomas revealed positivity only of angiogenic vessels.
  • These results support a novel histogenesis of angiomyolipoma as a defect in differentiation of stem cell precursors.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - SV7tert (CVCL_3602) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1982 Dec 1;156(6):1755-66 [7175440.001]
  • [Cites] Dev Biol. 1981 Apr 15;83(1):154-65 [7016634.001]
  • [Cites] Mayo Clin Proc. 1991 Aug;66(8):792-6 [1861550.001]
  • [Cites] Neuron. 1991 Aug;7(2):209-20 [1873027.001]
  • [Cites] Science. 1991 Oct 25;254(5031):571-3 [1658930.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Aug 21;68(2):193-201 [1394967.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1305-15 [8269512.001]
  • [Cites] Genes Dev. 1994 Aug 15;8(16):1875-87 [7958863.001]
  • [Cites] Genes Dev. 1994 Aug 15;8(16):1888-96 [7958864.001]
  • [Cites] Hum Mol Genet. 1994;3 Spec No:1477-80 [7849741.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11279-83 [7479979.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):400-6 [8755927.001]
  • [Cites] J Neurosci Res. 1996 Feb 1;43(3):299-314 [8714519.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15294-8 [8986805.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1639-47 [9403714.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):21-40 [9503504.001]
  • [Cites] Am J Hum Genet. 1998 Apr;62(4):810-5 [9529362.001]
  • [Cites] Cancer Res. 1998 Nov 1;58(21):4766-70 [9809973.001]
  • [Cites] J Cell Sci. 1999 Mar;112 ( Pt 6):905-15 [10036240.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):295-9 [10088548.001]
  • [Cites] Development. 1999 Jun;126(11):2495-503 [10226008.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2869-74 [10383148.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):117-22 [16001072.001]
  • [Cites] J Biol Chem. 2006 Aug 4;281(31):21582-7 [16737956.001]
  • [Cites] J Cell Sci. 1999 Dec;112 ( Pt 24):4739-49 [10574721.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28625-33 [10889192.001]
  • [Cites] J Clin Invest. 2000 Oct;106(8):963-71 [11032856.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):48-57 [11244503.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):483-91 [11485907.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1541-54 [11583980.001]
  • [Cites] Dev Dyn. 2001 Oct;222(2):218-27 [11668599.001]
  • [Cites] FASEB J. 2002 Apr;16(6):586-8 [11919162.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):781-6 [12213705.001]
  • [Cites] Neurobiol Dis. 2003 Nov;14(2):279-90 [14572449.001]
  • [Cites] J Urol. 1986 Jun;135(6):1121-4 [3520013.001]
  • (PMID = 17592550.001).
  • [ISSN] 1076-1551
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / P30 AR 42687; United States / NIAMS NIH HHS / AR / R01 AR050727; United States / NIAMS NIH HHS / AR / P30 AR042687; United States / NIAMS NIH HHS / AR / R01AR 47901; United States / NIAMS NIH HHS / AR / R01 AR 050727; United States / NIAMS NIH HHS / AR / R01 AR047901
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Biomarkers, Tumor; 0 / Leukocyte L1 Antigen Complex; 0 / Proteoglycans; 0 / chondroitin sulfate proteoglycan 4
  • [Other-IDs] NLM/ PMC1892760
  •  go-up   go-down


3. Yuan W, Wang W, Cui B, Su T, Ge Y, Jiang L, Zhou W, Ning G: Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry. Endocr Relat Cancer; 2008 Mar;15(1):343-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry.
  • To analyze the genetic alterations of pheochromocytomas and evaluate the difference among malignant, extra-adrenal, and benign pheochromocytomas.
  • Forty-three tumor samples were tested for genetic changes using multiplex ligation-dependent probe amplification.
  • All 43 patients (24 women and 19 men; mean age 44.6+/-13.6 years; range 18-75 years; 9 with malignant, 7 extra-adrenal, and 27 benign) showed multiple copy number losses or gains.
  • The average copy number change was 13.10 in malignant, 13.93 in benign, and 13.47 in paraganglioma patients.
  • However, we discovered that in the malignant pheochromocytomas, 6 of the 9 patients (67%) showed erythroblastic leukemia viral oncogene homolog 2 (ERBB-2) oncogene gain, whereas only 12 of the 34 (35%) identified change in the benign and extra-adrenal pheochromocytomas.
  • Further, IHC confirmed that ERBB-2-positive staining was more frequent and stronger in malignant pheochromocytomas than in benign and extra-adrenal pheochromocytomas.
  • The results suggest that there may be certain progression of genetic events that involves chromosomes 1p, 3p, 6p, 11q, 12q, 17q, and 19q in the development of pheochromocytomas, and the activation of ERBB-2 located on chromosome 17q is an important and early event in the malignancy development of these tumor types.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Gene Amplification. Genes, erbB-2 / genetics. Paraganglioma / genetics. Pheochromocytoma / classification. Pheochromocytoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Neoplasms / genetics. Brain Neoplasms / secondary. Chromosomes, Human / genetics. Female. Genome, Human. Humans. Immunoenzyme Techniques. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Lung Neoplasms / genetics. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Feb;156(2):651-9 [10666394.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):453-62 [17639058.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):11-3 [11464859.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):1955-60 [11994324.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Nucleic Acids Res. 2002 Jun 15;30(12):e57 [12060695.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1449-53 [12670888.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Dec;59(6):707-15 [14974911.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1119-28 [15167935.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):423-36 [15369446.001]
  • [Cites] Science. 1986 Jun 27;232(4758):1644-6 [3012781.001]
  • [Cites] Jpn J Cancer Res. 1990 Jun-Jul;81(6-7):632-8 [1976119.001]
  • [Cites] Cancer Res. 1992 Feb 15;52(4):770-4 [1346584.001]
  • [Cites] Jpn J Cancer Res. 1993 Apr;84(4):402-8 [8514606.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 May;38(5):531-7 [8101147.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1531-8 [8105382.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Jul;13(3):151-6 [7669733.001]
  • [Cites] Medicine (Baltimore). 1997 Nov;76(6):381-91 [9413424.001]
  • [Cites] Oncogene. 1998 Oct 29;17(17):2235-49 [9811454.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Mol Cell. 1998 Nov;2(5):581-91 [9844631.001]
  • [Cites] N Engl J Med. 1999 Jun 17;340(24):1872-9 [10369850.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Mar;42(3):260-8 [15609347.001]
  • [Cites] Diagn Mol Pathol. 2005 Mar;14(1):9-16 [15714058.001]
  • [Cites] J Pathol. 2005 Mar;205(4):514-21 [15685687.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):263-72 [15947101.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):83-93 [16215979.001]
  • [Cites] Lab Invest. 2005 Dec;85(12):1481-8 [16127456.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2729-31 [16790714.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Jun;21(3):509-25; ix [17548037.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):353-9 [10934139.001]
  • (PMID = 18310300.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2254511
  •  go-up   go-down


Advertisement
4. Deryugina EI, Quigley JP: Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta; 2010 Jan;1803(1):103-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions.
  • A number of extensive reviews are available discussing the roles of MMPs in various aspects of cancer progression from benign tumor formation to overt cancer present with deadly metastases.
  • This review will focus specifically on the evidence functionally linking the MMPs and tumor-induced angiogenesis in various in vivo models.
  • Emphasis has been placed on the cellular origin of the MMPs in tumor tissue, the requirement of proMMP activation and the resulting proteolytic activity for the induction and progression of tumor angiogenesis, and the pleiotropic roles for some of the MMPs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7968-75 [16912171.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12493-8 [16891410.001]
  • [Cites] Cell Cycle. 2006 Aug;5(15):1597-601 [16880743.001]
  • [Cites] J Cell Biol. 2006 Oct 9;175(1):179-91 [17030988.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):558-64 [15363807.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6965-72 [15466188.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):409-21 [15488763.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 Sep-Oct;1(6):475-9 [1302560.001]
  • [Cites] J Cell Biol. 1993 Sep;122(6):1351-9 [8376467.001]
  • [Cites] Hybridoma. 1993 Aug;12(4):349-63 [8244415.001]
  • [Cites] Nature. 1994 Jul 7;370(6484):61-5 [8015608.001]
  • [Cites] Microvasc Res. 1994 Jan;47(1):31-40 [7517489.001]
  • [Cites] Cell. 1994 Oct 21;79(2):315-28 [7525077.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Cell. 1996 May 31;85(5):683-93 [8646777.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):30174-80 [8939968.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):26-45 [9034785.001]
  • [Cites] Cell. 1997 Mar 21;88(6):801-10 [9118223.001]
  • [Cites] J Clin Invest. 1997 Apr 1;99(7):1534-45 [9119997.001]
  • [Cites] Lab Invest. 1997 Oct;77(4):345-55 [9354769.001]
  • [Cites] Cell. 1998 Feb 6;92(3):391-400 [9476898.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1048-51 [9500469.001]
  • [Cites] Cell. 1998 May 1;93(3):411-22 [9590175.001]
  • [Cites] Eur J Immunol. 1998 Jun;28(6):1773-84 [9645358.001]
  • [Cites] Am J Pathol. 1998 Sep;153(3):757-65 [9736026.001]
  • [Cites] Am J Pathol. 2008 Dec;173(6):1736-46 [18988801.001]
  • [Cites] Histochem Cell Biol. 2008 Dec;130(6):1119-30 [19005674.001]
  • [Cites] Nature. 2008 Dec 11;456(7223):809-13 [18997771.001]
  • [Cites] Nature. 2008 Dec 11;456(7223):814-8 [18997773.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):21-34 [19111878.001]
  • [Cites] Matrix Biol. 2009 Jan;28(1):3-10 [19010413.001]
  • [Cites] J Cell Biol. 2009 Feb 9;184(3):399-408 [19188491.001]
  • [Cites] Dev Cell. 2009 Feb;16(2):222-31 [19217424.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1517-26 [19208838.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):232-9 [19249681.001]
  • [Cites] Cell. 2009 Mar 6;136(5):839-51 [19217150.001]
  • [Cites] Clin Exp Metastasis. 2009;26(4):381-97 [18958576.001]
  • [Cites] J Cell Biol. 2009 Apr 6;185(1):11-9 [19332889.001]
  • [Cites] Int J Exp Pathol. 2009 Jun;90(3):222-31 [19563607.001]
  • [Cites] J Biol Chem. 2009 Sep 18;284(38):25854-66 [19608737.001]
  • [Cites] Curr Opin Cell Biol. 2009 Oct;21(5):645-53 [19616423.001]
  • [Cites] J Leukoc Biol. 2009 Nov;86(5):1065-73 [19741157.001]
  • [Cites] FASEB J. 2005 Feb;19(2):234-6 [15550552.001]
  • [Cites] Breast Dis. 2004;20:145-53 [15687715.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):211-7 [15766659.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):265-72 [15781313.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3200-8 [15833851.001]
  • [Cites] Genes Dev. 2005 Apr 15;19(8):979-91 [15805464.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78 [15863032.001]
  • [Cites] Circ Res. 2005 May 13;96(9):930-8 [15890980.001]
  • [Cites] J Cell Sci. 2005 May 15;118(Pt 10):2143-53 [15855236.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3967-79 [15899784.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):849-60 [15729716.001]
  • [Cites] J Cell Biol. 2005 May 23;169(4):681-91 [15911882.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):21882-92 [15824107.001]
  • [Cites] Exp Cell Res. 2005 Jul 15;307(2):292-304 [15950618.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):292-8 [15979458.001]
  • [Cites] Cell. 2005 Jul 1;121(7):1109-21 [15989959.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):2890-9 [16116175.001]
  • [Cites] J Exp Med. 2005 Sep 5;202(5):663-71 [16147977.001]
  • [Cites] Anticancer Drugs. 2005 Oct;16(9):997-1002 [16162976.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):211-26 [16169466.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1399-408 [16170032.001]
  • [Cites] J Exp Med. 2005 Sep 19;202(6):739-50 [16157686.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):299-309 [16226705.001]
  • [Cites] J Cell Biochem. 2005 Dec 1;96(5):897-905 [16149080.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):1-8 [15920734.001]
  • [Cites] Circ Res. 2005 Nov 25;97(11):1093-107 [16306453.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1429-37 [12368215.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] J Cell Mol Med. 2002 Jul-Sep;6(3):439-46 [12417062.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):561-73 [12492497.001]
  • [Cites] J Cell Biol. 2003 Jan 20;160(2):267-77 [12527751.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2002 Dec;37(6):375-536 [12540195.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] Vet Pathol. 2003 May;40(3):227-36 [12724562.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2454-61 [12750266.001]
  • [Cites] Nat Med. 2003 Jun;9(6):702-12 [12778169.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):153-66 [12784994.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;996:49-60 [12799282.001]
  • [Cites] Trends Cell Biol. 2003 Jul;13(7):366-75 [12837607.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):589-601 [12842087.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):932-6 [16355210.001]
  • [Cites] Blood. 2006 Jan 1;107(1):317-27 [16174763.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):259-66 [16397239.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2006;46:301-15 [16402907.001]
  • [Cites] Cell. 2006 Jan 13;124(1):175-89 [16413490.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):310-8 [16406506.001]
  • [Cites] Nat Methods. 2006 Apr;3(4):259-61 [16554829.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):728-34 [16524717.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):9-34 [16680569.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):35-43 [16680570.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):77-86 [16680574.001]
  • [Cites] Cell Cycle. 2006 Apr;5(8):812-7 [16627996.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5234-41 [16707448.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6149-55 [16778188.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7766-74 [16885380.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):159-66 [16857321.001]
  • [Cites] FASEB J. 2007 Aug;21(10):2580-91 [17392479.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):893-904 [17618273.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):800-8 [17851543.001]
  • [Cites] Bioessays. 2007 Nov;29(11):1159-68 [17935210.001]
  • [Cites] Mol Biol Cell. 2007 Nov;18(11):4222-31 [17699594.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):717-24 [17717634.001]
  • [Cites] Mol Cell Biol. 2007 Dec;27(24):8454-65 [17908800.001]
  • [Cites] Matrix Biol. 2007 Oct;26(8):587-96 [17669641.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20262-7 [18077379.001]
  • [Cites] Science. 2008 Jan 11;319(5860):163-4 [18187643.001]
  • [Cites] Science. 2008 Jan 11;319(5860):195-8 [18187653.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):181-3 [18328420.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):193-205 [18328424.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):206-20 [18328425.001]
  • [Cites] Curr Opin Hematol. 2008 May;15(3):197-203 [18391785.001]
  • [Cites] Neoplasia. 2008 Apr;10(4):329-40 [18392134.001]
  • [Cites] Cardiovasc Res. 2008 May 1;78(2):203-12 [18079100.001]
  • [Cites] Annu Rev Biochem. 2008;77:383-414 [18366325.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17740-8 [18441011.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):144-53 [18556780.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):579-91 [18596824.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):592-603 [18650835.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6251-9 [18676849.001]
  • [Cites] Cell. 2008 Aug 22;134(4):679-91 [18724940.001]
  • [Cites] J Biol Chem. 2008 Nov 7;283(45):30433-7 [18650443.001]
  • [Cites] Methods Enzymol. 2008;444:21-41 [19007659.001]
  • [Cites] Methods Enzymol. 2008;444:255-69 [19007668.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2108-14 [18772495.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4340-51 [14530359.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3262-9 [12855577.001]
  • [Cites] Nat Genet. 2003 Nov;35(3):252-7 [14517555.001]
  • [Cites] Cell Tissue Res. 2003 Oct;314(1):15-23 [12883993.001]
  • [Cites] Brain. 2003 Dec;126(Pt 12):2738-49 [14506071.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5370-5 [14638740.001]
  • [Cites] Blood. 2004 Jan 1;103(1):110-9 [12958067.001]
  • [Cites] Leuk Res. 2004 Mar;28(3):221-2 [14687614.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):71-8 [14708027.001]
  • [Cites] Circ Res. 2004 Feb 6;94(2):262-8 [14670843.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1675-86 [14996727.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1687-94 [14996728.001]
  • [Cites] Semin Thromb Hemost. 2004 Feb;30(1):109-17 [15034802.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13564-74 [14729679.001]
  • [Cites] J Cell Sci. 2004 Apr 1;117(Pt 9):1847-57 [15075244.001]
  • [Cites] J Cell Physiol. 2004 Jul;200(1):11-9 [15137053.001]
  • [Cites] J Histochem Cytochem. 2004 Jun;52(6):711-22 [15150280.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5304-13 [15169894.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):163-76 [10652271.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):361-81 [10666364.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2202-7 [10681423.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1641-6 [9811357.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6845-52 [9862716.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):35-48 [9887098.001]
  • [Cites] APMIS. 1999 Jan;107(1):38-44 [10190278.001]
  • [Cites] Blood. 1999 May 1;93(9):3064-73 [10216103.001]
  • [Cites] J Biol Chem. 1999 May 7;274(19):13066-76 [10224058.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] Exp Cell Res. 1999 Jul 10;250(1):122-30 [10388526.001]
  • [Cites] EMBO J. 1999 Jul 15;18(14):3964-72 [10406801.001]
  • [Cites] Cell. 1999 Jul 23;98(2):137-46 [10428026.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):757-67 [15545316.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):769-81 [15557125.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1292-8 [15516694.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27633-45 [15066996.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):617-29 [15286728.001]
  • [Cites] J Clin Invest. 2004 Sep;114(5):623-33 [15343380.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1102-13 [10713697.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):15-23 [10728589.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3884-9 [10760260.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4052-7 [10737763.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1647-54 [10815882.001]
  • [Cites] J Biol Chem. 2000 Aug 25;275(34):26411-5 [10827175.001]
  • [Cites] Exp Cell Res. 2000 Oct 10;260(1):73-84 [11010812.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12227-32 [11035804.001]
  • [Cites] Cell. 2000 Oct 27;103(3):481-90 [11081634.001]
  • [Cites] FEBS Lett. 2000 Dec 15;486(3):247-51 [11119712.001]
  • [Cites] Hybridoma. 2000 Oct;19(5):375-85 [11128027.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(1-2):109-20 [11191049.001]
  • [Cites] Biochim Biophys Acta. 2000 Dec 11;1499(1-2):19-33 [11118636.001]
  • [Cites] Methods Mol Biol. 2001;151:411-5 [11217316.001]
  • [Cites] Exp Cell Res. 2001 Feb 15;263(2):209-23 [11161720.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Mar;42(3):853-9 [11222550.001]
  • [Cites] J Exp Med. 2001 Mar 19;193(6):727-40 [11257139.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2323-32 [11290594.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 30;282(2):463-73 [11401482.001]
  • [Cites] J Leukoc Biol. 2001 Jun;69(6):851-9 [11404367.001]
  • [Cites] J Clin Invest. 2001 Aug;108(3):349-55 [11489925.001]
  • [Cites] J Cell Biol. 2001 Sep 3;154(5):1069-79 [11535623.001]
  • [Cites] Cancer Lett. 2001 Nov 28;173(2):175-82 [11597792.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12485-90 [11606713.001]
  • [Cites] Radiology. 2001 Nov;221(2):523-9 [11687699.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Cell. 2001 Dec 14;107(6):789-800 [11747814.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):272-81 [11803470.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):580-8 [11809713.001]
  • [Cites] Acta Haematol. 2001;106(4):162-9 [11815713.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):7377-85 [11741954.001]
  • [Cites] FASEB J. 2002 Mar;16(3):379-89 [11874987.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):9749-56 [11724803.001]
  • [Cites] FASEB J. 2002 Apr;16(6):555-64 [11919158.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] J Hematother Stem Cell Res. 2002 Apr;11(2):207-14 [11983094.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Cell. 2002 May 31;109(5):625-37 [12062105.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42 [12165638.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36288-95 [12114504.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5580-9 [12359771.001]
  • [Cites] Cell. 2003 Jul 11;114(1):33-45 [12859896.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5060-4 [12941835.001]
  • [Cites] Eur J Biochem. 2003 Sep;270(18):3739-49 [12950257.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5224-9 [14500349.001]
  • [Cites] J Leukoc Biol. 2006 Dec;80(6):1183-96 [16997855.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11089-93 [17145848.001]
  • [Cites] Clin Exp Metastasis. 2006;23(7-8):335-44 [17136575.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33 [17318226.001]
  • [Cites] Biochim Biophys Acta. 2007 Mar;1773(3):400-7 [17187878.001]
  • [Cites] J Biol Chem. 2007 Mar 2;282(9):6899-905 [17204469.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2649-56 [17363585.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3310-9 [17409440.001]
  • [Cites] Mol Cell Proteomics. 2007 Apr;6(4):611-23 [17200105.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):765-70 [17429393.001]
  • [Cites] J Cell Sci. 2007 May 1;120(Pt 9):1607-14 [17405818.001]
  • [Cites] Lancet Oncol. 2007 May;8(5):444-8 [17466902.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4353-63 [17483349.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):3068-78 [17505010.001]
  • (PMID = 19800930.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA105412; United States / NCI NIH HHS / CA / R01 CA055852-16; United States / NCI NIH HHS / CA / CA055852-16; United States / NCI NIH HHS / CA / R01 CA055852; United States / NCI NIH HHS / CA / R01 CA129484
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 240
  • [Other-IDs] NLM/ NIHMS154042; NLM/ PMC2824055
  •  go-up   go-down


5. Chaddad Neto F, Lopes A, Alberto Filho M, Catanoce A, Joaquim AF, Oliveira Ed: Tectal glioblastoma. Arq Neuropsiquiatr; 2007 Dec;65(4A):996-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain stem gliomas are a heterogeneous group of neoplasms arising mostly in paediatric patients.
  • Tectal plate gliomas represent a particular type of brain stem tumours usually with a benign, indolent clinical course, presenting with signs of raised intracranial hypertension due to supra-tentorialhydrocephalous caused by aqueductal stenosis.
  • [MeSH-major] Brain Neoplasms. Glioblastoma. Tectum Mesencephali

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094862.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


6. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, Jegga AG, Li H, Upadhyaya M, Giovannini M, Muir D, Wallace MR, Lopez E, Serra E, Nielsen GP, Lazaro C, Stemmer-Rachamimov A, Page G, Aronow BJ, Ratner N: Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med; 2009 Jul;1(4):236-48
Guide to Pharmacology. gene/protein/disease-specific - ADGRG6 - data and references .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used gene expression profiling to define transcriptional changes between primary normal Schwann cells (n = 10), NF1-derived primary benign neurofibroma Schwann cells (NFSCs) (n = 22), malignant peripheral nerve sheath tumour (MPNST) cell lines (n = 13), benign neurofibromas (NF) (n = 26) and MPNST (n = 6).

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci Res. 2004 Dec 15;78(6):796-802 [15523643.001]
  • [Cites] J Neurosci. 1998 Jan 1;18(1):237-50 [9412504.001]
  • [Cites] Dev Cell. 2005 Feb;8(2):179-92 [15691760.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8633-8 [15932943.001]
  • [Cites] Nat Rev Neurosci. 2005 Sep;6(9):671-82 [16136171.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e175 [16284200.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):265-76 [16283621.001]
  • [Cites] J Clin Pathol. 2006 Feb;59(2):160-5 [16443732.001]
  • [Cites] BMC Bioinformatics. 2006;7:35 [16430768.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] BMC Bioinformatics. 2006;7:84 [16504070.001]
  • [Cites] Hum Mutat. 2006 Jul;27(7):716 [16786508.001]
  • [Cites] Development. 2006 Aug;133(15):2875-86 [16790476.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):593-602 [16862190.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D116-21 [17178752.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):398-407 [17202312.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4609-16 [17297459.001]
  • [Cites] Neuroscience. 2007 Jul 29;147(4):928-37 [17582688.001]
  • [Cites] Development. 2007 Sep;134(18):3271-81 [17699610.001]
  • [Cites] Genome Biol. 2007;8(9):R183 [17784955.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):105-16 [18242511.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):129-40 [18242513.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1015-24 [18281533.001]
  • [Cites] Cell Stem Cell. 2008 Jul 3;3(1):33-43 [18593557.001]
  • [Cites] Glia. 2008 Nov 1;56(14):1590-605 [18803326.001]
  • [Cites] Cell Stem Cell. 2008 Dec 4;3(6):658-69 [19041782.001]
  • [Cites] Cell Stem Cell. 2009 May 8;4(5):453-63 [19427294.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 1;27(5):1359-64 [9973626.001]
  • [Cites] Hum Mol Genet. 2000 Jan 22;9(2):237-47 [10607834.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Feb;27(2):117-23 [10612798.001]
  • [Cites] Am J Epidemiol. 2000 Jan 1;151(1):33-40 [10625171.001]
  • [Cites] Mol Cell Biol. 2000 May;20(9):3198-209 [10757804.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1233-41 [10791998.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30740-5 [10900196.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3055-64 [11115850.001]
  • [Cites] Genes Dev. 2001 Jan 1;15(1):66-78 [11156606.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Nat Genet. 2001 Jul;28(3):294-6 [11431704.001]
  • [Cites] Behav Brain Res. 2001 Nov 1;125(1-2):279-84 [11682119.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):41229-36 [11514554.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):702-9 [12152785.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2213-24 [12612091.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Apr 15;28(8):755-63 [12698117.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] J Neurosci. 2004 Mar 10;24(10):2357-65 [15014110.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3763-71 [15173083.001]
  • [Cites] Brain Pathol. 2004 Jul;14(3):258-64 [15446580.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):645-53 [1696266.001]
  • [Cites] Glia. 1996 Aug;17(4):327-38 [8856329.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [CommentIn] EMBO Mol Med. 2009 Jul;1(4):198-200 [20049721.001]
  • (PMID = 20049725.001).
  • [ISSN] 1757-4684
  • [Journal-full-title] EMBO molecular medicine
  • [ISO-abbreviation] EMBO Mol Med
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K01 NS049191; United States / NCI NIH HHS / CA / T32 CA059268; United States / NINDS NIH HHS / NS / K01-NS049191; United States / NCI NIH HHS / CA / T32 CA 59268
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SOX9 Transcription Factor; 0 / SOX9 protein, human
  • [Other-IDs] NLM/ PMC3378132
  •  go-up   go-down


7. Aruga J, Nozaki Y, Hatayama M, Odaka YS, Yokota N: Expression of ZIC family genes in meningiomas and other brain tumors. BMC Cancer; 2010;10:79
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of ZIC family genes in meningiomas and other brain tumors.
  • METHODS: We examined the mRNA and protein expression of human ZIC1, ZIC2, ZIC3, ZIC4 and ZIC5 genes in meningiomas in comparison to other brain tumors, using RT-PCR, analysis of published microarray data, and immunostaining.
  • RESULTS: ZIC1, ZIC2 and ZIC5 transcript levels in meningiomas were higher than those in whole brain or normal dura mater, whereas all five ZIC genes were abundantly expressed in medulloblastomas.
  • The expression level of ZIC1 in public microarray data was greater in meningiomas classified as World Health Organization Grade II (atypical) than those classified as Grade I (benign).
  • The pattern of ZIC expression in both of these tumor types may reflect the properties of the tissues from which the tumors are derived.
  • [MeSH-major] Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Meningioma / metabolism
  • [MeSH-minor] Animals. Cell Differentiation. Cell Proliferation. Humans. Immunohistochemistry / methods. Mice. NIH 3T3 Cells. Nuclear Proteins / biosynthesis. Stem Cells. Transcription Factors / biosynthesis. Vimentin / biosynthesis. Zinc Fingers

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurg Focus. 2007;23(4):E3 [17961040.001]
  • [Cites] Dev Biol. 2007 Jun 15;306(2):669-84 [17490632.001]
  • [Cites] Physiol Genomics. 1999 Aug 31;1(2):83-91 [11015565.001]
  • [Cites] J Neurosci. 2002 Jan 1;22(1):218-25 [11756505.001]
  • [Cites] Neurology. 2002 Dec 24;59(12):1985-7 [12499499.001]
  • [Cites] Mol Cell Neurosci. 2004 Jun;26(2):205-21 [15207846.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):377-83 [8542595.001]
  • [Cites] Clin Genet. 2005 Apr;67(4):290-6 [15733262.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2575-83 [15880380.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Nucleic Acids Res. 2007;35(7):e51 [17344319.001]
  • [Cites] J Neuroimmunol. 2008 Sep 15;201-202:163-5 [18639938.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):346-51 [19003955.001]
  • [Cites] J Neurol. 2010 Apr;257(4):509-17 [20035430.001]
  • [Cites] J Neurosci. 2008 Apr 30;28(18):4712-25 [18448648.001]
  • (PMID = 20199689.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Vimentin; 0 / ZIC1 protein, human; 0 / ZIC2 protein, human; 0 / ZIC5 protein, human
  • [Other-IDs] NLM/ PMC2838823
  •  go-up   go-down


8. Cozzi L, Clivio A, Bauman G, Cora S, Nicolini G, Pellegrini R, Vanetti E, Yartsev S, Fogliata A: Comparison of advanced irradiation techniques with photons for benign intracranial tumours. Radiother Oncol; 2006 Aug;80(2):268-73
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of advanced irradiation techniques with photons for benign intracranial tumours.
  • BACKGROUND AND PURPOSE: The potential benefits and limitations of different radiation techniques (stereotactic arc therapy (SRS/T), intensity modulated radiotherapy (IMRT), helical tomotherapy (HT), Cyberknife and intensity-modulated multiple arc therapy (AMOA)) have been assessed using comparative treatment planning methods on twelve patients presenting with 'benign' brain tumours.
  • For organs at risk all techniques respected planning objectives with a tendency of Cyberknife and SRS/T to better spare the brain stem and the healthy brain tissue (e.g., V(20Gy) of 2.0% and 2.3%, respectively, compared to 3.1-5.0% for the other techniques).
  • [MeSH-major] Brain Neoplasms / radiotherapy. Photons / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890315.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


9. Tarnaris A, Fernandes RP, Kitchen ND: Does conservative management for brain stem cavernomas have better long-term outcome? Br J Neurosurg; 2008 Dec;22(6):748-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does conservative management for brain stem cavernomas have better long-term outcome?
  • There has been a controversy in the last 15 years on the correct management of brain stem cavernomas.
  • The natural history of brain stem cavernomas appears more benign than previously thought.
  • [MeSH-major] Brain Stem / surgery. Brain Stem Neoplasms / therapy. Cerebral Hemorrhage / therapy. Hemangioma, Cavernous, Central Nervous System / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19085358.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


10. Yao Y, Tang X, Li S, Mao Y, Zhou L: Brain tumor stem cells: view from cell proliferation. Surg Neurol; 2009 Mar;71(3):274-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor stem cells: view from cell proliferation.
  • A small population of TSCs, which form neurospheres and possess the capacity for self-renewal, has been recently identified in adult and pediatric brain tumors.
  • They differentiate into phenotypically diverse populations, including neuronal, astrocytic, and oligodendroglial cells in vitro and recapitulate original tumors in vivo.
  • The understanding of brain TSCs has been greatly advanced by the knowledge of cell proliferation, which contributes to initiate and sustain the malignant phenotype.
  • In this article, the authors summarized the evidence of the presence of TSCs in human brain tumors and emphasized the significance of the proliferative status of TSCs.
  • Finally, the preliminary evidence that TSCs in malignant brain tumors have more proliferative capacity than stem/progenitor cells in benign brain tumors was discussed.
  • [MeSH-major] Adult Stem Cells / pathology. Brain Neoplasms / pathology. Neoplastic Stem Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249579.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


11. Nakaya K, Niranjan A, Kondziolka D, Kano H, Khan AA, Nettel B, Koebbe C, Pirris S, Flickinger JC, Lunsford LD: Gamma knife radiosurgery for benign tumors with symptoms from brainstem compression. Int J Radiat Oncol Biol Phys; 2010 Jul 15;77(4):988-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife radiosurgery for benign tumors with symptoms from brainstem compression.
  • PURPOSE: This study evaluated the role of radiosurgery in the management of symptomatic patients with brainstem compression from benign basal tumors.
  • METHODS AND MATERIALS: Over a 17-year, period 246 patients (202 vestibular schwannomas and 44 meningiomas) with brainstem compression from benign skull-base tumors were managed with Gamma Knife radiosurgery.
  • Median tumor volumes were 3.9 cm(3) (range, 0.8-39.0 mL) and 6.6 mL (range, 1.6-25.1 mL) for vestibular schwannomas and meningiomas, respectively.
  • For both tumors, a median marginal dose of 13 Gy was prescribed.
  • Patients were categorized into four groups on the basis of the tumor-brainstem relationship on neuroimaging.
  • RESULTS: Preservation of function was stratified according to grade of brainstem compression.
  • We analyzed the effect of radiosurgery on symptoms of brainstem compression.
  • The tumor control rate was 100 % for meningioma and 97% for vestibular schwannomas (although 5% required an additional procedure such as a ventriculoperitoneal shunt).
  • Balance improved significantly in patients who had less tumor compression (p = 0.0357) after radiosurgery.
  • CONCLUSION: Radiosurgery is a minimally invasive option for patients with benign basal tumors that indent or distort the brainstem.
  • A high tumor growth control rate and satisfactory rate of neurological preservation and symptom control can be obtained with radiosurgery.
  • [MeSH-major] Brain Stem. Meningeal Neoplasms / surgery. Meningioma / surgery. Neuroma, Acoustic / surgery. Radiosurgery / methods. Skull Base Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20381265.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Tunici P, Yu JS: Pituitary adenoma stem cells. Methods Mol Biol; 2009;568:195-201
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary adenoma stem cells.
  • The identification of a subpopulation of brain tumor cells with potent tumorigenic capacity strengthens the cancer stem cell hypothesis of the origin of the tumors that has recently attracted the attention of many researchers.
  • Reports have been published on the identification of tumor cells with stem cells characteristics in different types of tumors (acute myelogenic leukemia, breast cancer, prostate cancer, bone sarcomas, liver cancer, and melanomas).
  • We and other groups have previously reported the isolation of cancer stem cells from adult glioblastoma multiforme.
  • These cells express stem cell markers, and when differentiated they express glial and neuronal markers.
  • In vivo they give a tumor that recapitulates the characteristics of the tumor in the patient.
  • More recently we have isolated tumor stem-like cells also from benign tumors like pituitary adenomas.
  • Cells derived from pituitary adenomas are able to grow as floating aggregates resembling the neurospheres (typical of normal stem cells) in a medium supplemented by growth factors (EGF and bFGF).
  • The immunocytochemical analysis revealed that pituitary tumor stem-like cells are positives for nestin and, when grown for ten days in differentiation medium they express GFAP, BIII tubulin, and S-100.
  • In vitro tumor stem-like cells derived from a patient with a somatotroph adenoma showed high production of growth hormone and prolactin, while cells derived from the same patient but grown in presence of fetal bovine serum showed no production of hormones.
  • [MeSH-major] Cell Culture Techniques / methods. Neoplastic Stem Cells / pathology. Pituitary Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582428.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 9002-62-4 / Prolactin
  •  go-up   go-down


13. Pascual Castroviejo I, Pascual Pascual S, Velázquez Fragua R, Viaño J, Garcia Segura JM: [Brain stem tumors associated with neurofibromatosis type 1. Presentation of 20 infantile patients]. Neurologia; 2007 Dec;22(10):846-52
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brain stem tumors associated with neurofibromatosis type 1. Presentation of 20 infantile patients].
  • [Transliterated title] Tumores de tronco cerebral asociados con neurofibromatosis tipo 1. Presentación de 20 pacientes infantiles.
  • OBJECTIVE: To describe the clinical and imaging findings of 20 patients (12 women and 8 men) with brain stem tumors associated with neurofibromatosis type 1 (NF1).
  • Thirteen of the 20 patients (65 %) also had optic pathway tumor.
  • Brain stem tumor identification occurred at the same time as NF1 in the patients who were studied by MR at the time of the first consult.
  • RESULTS: Brain stem identification occurred at the same time as that of the NF1 in patients who were studied by MR from the beginning.
  • Diffuse or localized medullary enlargement was the most frequent MR imaging and appeared in 13 patients (65%), followed by the tumor that involved all brain stem (pontine and medullary areas) that appeared in 6 patients (30 %).
  • In the last group, one tumor showed extension through brain stem and medial cerebellar parts, another was located in the aqueduct and in the periaqueductal areas and showed slow progressive growth, and one third patient had a tumor with aggressive signs in the SMR study.
  • Another patient had an aggressive tumor that involved the left optic nerve, chiasm, mesencephalon and upper right pontine areas.
  • The histological study of the tumoral biopsic tissue of the two last patients showed astrocitoma degree 1 (benign tumor).
  • The two aggressive tumors were treated with radiotheraphy and chemotherapy and they are still alive 4 and 7 years respectively after treatment.
  • Only one of the 20 patients died, although it was due to a malignant chiasmatic tumor, that had been treated twenty years before, and not by the brain stem tumor.
  • CONCLUSIONS: In NF1, brain stem tumors are the most frequent tumors of the posterior fossa and the second most frequent of the central nervous system (CNS).
  • MR and SMR are necessary to a correct identification of the tumor in some patients.
  • Most of these tumors are benign.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / diagnosis. Brain Stem. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Neurofibromatosis 1 / complications


14. Jinhu Y, Jianping D, Jun M, Hui S, Yepeng F: Metastasis of a histologically benign choroid plexus papilloma: case report and review of the literature. J Neurooncol; 2007 May;83(1):47-52
Genetic Alliance. consumer health - Choroid Plexus Papilloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of a histologically benign choroid plexus papilloma: case report and review of the literature.
  • Cerebrospinal metastases of benign choroid plexus papillomas (CPPs) are extremely rare.
  • Plain CT scan of the cranium revealed a partly calcified tumor filling the fourth ventricle and its right recess.
  • Cranial MRI showed an inhomogeneously contrast-enhancing tumor and leptomeningeal enhancement encasing the brain stem.
  • Complete resection of the tumor was carried out, and seedings to the floor of the fourth ventricle and cervico-medullary junction were found during the operation.
  • While intraoperative frozen section suggested pathology of papillary ependymoma or CPP, to our surprise, final histological examination revealed a benign choroid plexus papilloma.
  • Two months after the first operation, on follow-up MRI of the cranium, the leptomeningeal enhancement encasing the brain stem had resolved spontaneously.
  • This special case helps increase our understanding of benign CPPs and expands our differential diagnostic consideration of lesions with similar manifestations.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Cerebral Ventricle Neoplasms / secondary. Choroid Plexus Neoplasms / pathology. Choroid Plexus Neoplasms / secondary. Fourth Ventricle. Papilloma / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Neoplasm Seeding. Neurosurgical Procedures / adverse effects. Subarachnoid Space. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387433.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 33
  •  go-up   go-down


15. Ondik MP, Preston T, Towfighi J, Isaacson JE: Unilateral congenital facial nerve paralysis secondary to a benign epithelioid peripheral nerve sheath tumor. Otol Neurotol; 2007 Dec;28(8):1091-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral congenital facial nerve paralysis secondary to a benign epithelioid peripheral nerve sheath tumor.
  • OBJECTIVE: A benign epithelioid peripheral nerve sheath tumor is described in the setting of congenital facial nerve (FN) paralysis.
  • INTERVENTIONS: Auditory brainstem evoked potential study, gadolinium-enhanced magnetic resonance imaging, temporal bone computed tomography, and transmastoid FN decompression with tumor resection.
  • MAIN OUTCOME MEASURES: Follow-up for tumor recurrence and postoperative FN function.
  • RESULTS: The child underwent a transmastoid FN exploration with resection of a 0.6-cm spherical tumor analyzed to be a benign epithelioid peripheral nerve sheath tumor.
  • CONCLUSION: Benign epithelioid peripheral nerve sheath tumor can cause congenital facial nerve palsy.
  • [MeSH-major] Facial Nerve Diseases / congenital. Facial Nerve Diseases / etiology. Neoplasms, Glandular and Epithelial / complications. Neoplasms, Glandular and Epithelial / congenital. Nerve Sheath Neoplasms / complications. Nerve Sheath Neoplasms / congenital
  • [MeSH-minor] Decompression, Surgical. Evoked Potentials, Auditory, Brain Stem / physiology. Facial Nerve / physiology. Facial Paralysis / congenital. Facial Paralysis / etiology. Female. Gadolinium. Humans. Infant. Magnetic Resonance Imaging. Temporal Bone / radiography

  • Genetic Alliance. consumer health - paralysis.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084823.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


16. Hughes SA, Achanta P, Ho AL, Duenas VJ, Quiñones-Hinojosa A: Biological horizons for targeting brain malignancy. Adv Exp Med Biol; 2010;671:93-104
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological horizons for targeting brain malignancy.
  • Though currently available clinical treatments and therapies have clearly extended the survival of patients with brain tumors, many of these advances are short lived, particularly with respect to high grade gliomas such as glioblastoma multiforme.
  • The missing link to an efficacious treatment of high grade gliomas is a more complete understanding of the basic molecular and cellular origin of brain tumors.
  • However, new discoveries of stem cell and developmental neurobiology have now borne the cancer stem cell hypothesis, drawing off of intriguing similarities between benign and malignant cells within the central nervous system.
  • Investigation of cancer stem cell hypothesis and brain tumor propagation is the current frontier of stem cell and cancer biology.
  • "Molecular neurosurgery", glioma treatments involving biologics using neural stem cells to target the cancer at the level of individual migratory cell, is a rapidly evolving field.
  • This coming progression of applied cancer stem cell research, coupled with current modalities, promises more comprehensive brain cancer interventions.
  • [MeSH-major] Brain Neoplasms / therapy. Stem Cell Transplantation
  • [MeSH-minor] Drug Delivery Systems. Genetic Therapy / methods. Glioma / pathology. Glioma / therapy. Neurons / physiology. Stem Cells / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20455498.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Mpairamidis E, Alexiou GA, Stefanaki K, Sfakianos G, Prodromou N: Brainstem ganglioglioma. J Child Neurol; 2008 Dec;23(12):1481-3
Genetic Alliance. consumer health - Ganglioglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brainstem ganglioglioma.
  • Gangliogliomas are usually benign slow-growing neoplasms, seen mainly in the first 3 decades of life and are prevalently located supratentorial, mostly in the temporal and frontal lobe.
  • The authors present a rare case of a brainstem ganglioglioma in an 11-year-old boy who was referred to their hospital complaining of episodes of blurry vision, loss of memory, gait disturbances, and morning headache with vomiting, lasting for over a month.
  • Computed tomography and magnetic resonance imaging scans revealed a mass on the dorsal surface of the brainstem, compressing the brainstem and producing secondary obstructive hydrocephalus.
  • A total resection should be always attempted, where possible in brainstem gangliogliomas.
  • Close follow-up is mandatory, and re-resection or radiotherapy should be considered in case of tumor recurrence.
  • [MeSH-major] Brain Stem Neoplasms. Ganglioglioma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19073857.001).
  • [ISSN] 1708-8283
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Higashida T, Sakata K, Kanno H, Tanabe Y, Kawasaki T, Yamamoto I: [Intracranial chondroma arising from the skull base: two case reports featuring the image findings for differential diagnosis]. No Shinkei Geka; 2007 May;35(5):495-501
Genetic Alliance. consumer health - Chondroma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MRI showed a huge tumor occupying the bilateral cavernous sinus.
  • Partial removal of the tumor was performed through the left orbitozygomatic subtemporal approach.
  • MRI showed a brain stem infarction with a huge tumor located at the right middle fossa.
  • In these two cases, the histopathological diagnosis of the tumors was benign chondroma and the size of residual tumors have not changed for one year without any additional therapy.
  • The current popular surgical approach for parasellar tumors is transcranial such as the orbitozygomatic subtemporal approach.
  • [MeSH-major] Chondroma / diagnosis. Skull Base Neoplasms / diagnosis
  • [MeSH-minor] Adult. Brain Stem Infarctions / complications. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17491346.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Stark AM, Maslehaty H, Hugo HH, Mahvash M, Mehdorn HM: Glioblastoma of the cerebellum and brainstem. J Clin Neurosci; 2010 Oct;17(10):1248-51
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma of the cerebellum and brainstem.
  • Glioblastoma multiforme (GB) is the most common and most malignant primary intracranial tumor.
  • Because of its rarity and the non-specific radiological features of iGB, it can easily be misdiagnosed as a brain metastasis, ependymoma or even as a benign lesion such as vestibular schwannoma or meningioma.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Stem / pathology. Cerebellum / pathology. Glioblastoma / pathology

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20619657.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


20. Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, Hahm SA, Haider M, Head CS, Reiter RE, Rubin MA, Witte ON: Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate; 2010 Apr 1;70(5):491-501
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Prostate stem/progenitor cells function in glandular development and maintenance.
  • They may be targets for tumor initiation, so characterization of these cells may have therapeutic implications.
  • Cells from dissociated tissues that form spheres in vitro often represent stem/progenitor cells.
  • RESULTS: Prostate tissue specimens were heterogeneous, containing both benign and malignant (Gleason 3-5) glands.
  • Subpopulations of prostate cells expressing tumor-associated calcium signal transducer 2 (Trop2), CD44, and CD49f preferentially formed spheres.
  • The TMPRSS-ERG fusion was absent in prostaspheres derived from fusion-positive tumor tissue, suggesting a survival/growth advantage of benign prostate epithelial cells.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] Br J Cancer. 2000 Feb;82(4):990-7 [10732776.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20882-7 [19088204.001]
  • [Cites] Br J Cancer. 2001 Aug 17;85(4):590-9 [11506501.001]
  • [Cites] J Cell Sci. 2001 Nov;114(Pt 21):3865-72 [11719553.001]
  • [Cites] J Pathol. 2001 Dec;195(5):563-70 [11745692.001]
  • [Cites] Mol Cancer Res. 2002 Dec;1(2):113-21 [12496358.001]
  • [Cites] Genes Dev. 2003 May 15;17(10):1253-70 [12756227.001]
  • [Cites] Brain Res. 2003 Dec 12;993(1-2):18-29 [14642827.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3029-35 [14701873.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3539-45 [15226377.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7274-82 [15378087.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):209-14 [15368472.001]
  • [Cites] J Neurosci Res. 2004 Oct 15;78(2):215-23 [15378509.001]
  • [Cites] J Steroid Biochem Mol Biol. 1996 Nov;59(3-4):243-50 [9010316.001]
  • [Cites] Differentiation. 1998 Jul;63(3):131-40 [9697307.001]
  • [Cites] Hum Pathol. 1998 Sep;29(9):1005-12 [9744319.001]
  • [Cites] J Cell Physiol. 1999 Nov;181(2):304-11 [10497309.001]
  • [Cites] Acta Biochim Pol. 2005;52(2):353-8 [15990920.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9269-79 [16230388.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Nat Med. 2006 Mar;12(3):296-300 [16520777.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1880-5 [16574858.001]
  • [Cites] Cancer Cell. 2006 May;9(5):367-78 [16697957.001]
  • [Cites] Eur J Cancer. 2006 Jun;42(9):1213-8 [16632344.001]
  • [Cites] Brain Res. 2006 Aug 30;1107(1):82-96 [16859652.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8598-607 [16951173.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1253-61 [16990388.001]
  • [Cites] Nat Methods. 2006 Oct;3(10):801-6 [16990812.001]
  • [Cites] Mol Carcinog. 2007 Jan;46(1):1-14 [16921491.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):181-6 [17185413.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4807-15 [17510410.001]
  • [Cites] Prostate. 2007 Sep 15;67(13):1384-96 [17639507.001]
  • [Cites] Dev Biol. 2007 Dec 1;312(1):396-406 [17976567.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9703-11 [19047148.001]
  • [Cites] Prostate. 2001 Feb 1;46(2):142-53 [11170142.001]
  • (PMID = 19938015.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16042; United States / NIAID NIH HHS / AI / AI-28697; United States / NHGRI NIH HHS / HG / F31 HG000117; United States / NCI NIH HHS / CA / P30 CA016042; United States / NHGRI NIH HHS / HG / HG000117-05; United States / NIAID NIH HHS / AI / P30 AI028697; United States / NHGRI NIH HHS / HG / F31 HG000117-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD44; 0 / CD44 protein, human; 0 / Glycoproteins; 0 / Integrin alpha6; 0 / Oncogene Proteins, Fusion; 0 / Peptides; 0 / TMPRSS2-ERG fusion protein, human
  • [Other-IDs] NLM/ NIHMS187861; NLM/ PMC2885946
  •  go-up   go-down


21. Lázaro BC, Landeiro JA: Tectal plate tumors. Arq Neuropsiquiatr; 2006 Jun;64(2B):432-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tectal plate tumors.
  • Tectal plate is a rare location for a tumor.
  • Many papers have described different types of pathology arising in that location including tumors, vascular lesions, inflammatory and infectious processes.
  • Open surgery was performed in three cases (due to tumor enlargement or need for the exact diagnosis).
  • In our series, except in the metastatic tumor case and the cavernoma, the other types of lesion consisted of low grade gliomas.
  • These lesions represent a different type of brain stem tumor sharing a common good prognosis, with a benign behavior.
  • We believe that tectal tumors must be managed case by case.
  • When a patient presents with a benign lesions in the tectal region, treating the main symptom--hydrocephalus--should be the first attempt in management of these lesions.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Glioma / diagnosis. Tectum Mesencephali

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917614.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


22. Campos WK, Linhares MN: Sporadic intramedullary spinal cord hemangioblastoma in a newborn. Pediatr Neurosurg; 2010;46(5):385-9
Genetic Alliance. consumer health - Hemangioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hemangioblastomas (HB) are rare lesions accounting for 2% of all spinal cord tumors.
  • They are highly vascular, benign tumors that occur either sporadically or in the presence of von Hippel-Lindau disease.
  • MRI of the spine revealed an intramedullary tumor extending from level T6 to T12.
  • RESULTS: The tumor was excised completely, using standard microsurgical techniques via a posterior approach.
  • CONCLUSION: A review of the literature revealed that this neoplasm is composed of 3 major cell types: endothelial cells, pericytes and stromal cells.
  • Complete microsurgical removal is the treatment of choice for spinal cord HB because the tumor is benign.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Hemangioblastoma / surgery. Spinal Cord Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21389752.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Adamson DC, Rasheed BA, McLendon RE, Bigner DD: Central nervous system. Cancer Biomark; 2010;9(1-6):193-210
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several different types of tumors, benign and malignant, have been identified in the central nervous system (CNS).
  • The prognoses for these tumors are related to several factors, such as the age of the patient and the location and histology of the tumor.
  • In adults, about half of all CNS tumors are malignant, whereas in pediatric patients, more than 75% are malignant.
  • For most benign CNS tumors that require treatment, neurosurgeons can offer curative resections or at least provide significant relief from mass effect.
  • Unfortunately, we still lack effective treatments for most primary and secondary malignant CNS tumors.
  • However, the past decade has witnessed an explosion in the understanding of the early molecular events in malignant primary CNS tumors, and for the first time in history, oncologists are seeing that a plethora of new therapies targeting these molecular events are being tested in clinical trials.
  • There is hope on the horizon for the fight against these deadly tumors.
  • The distribution of CNS tumors by location has remained constant for numerous years.
  • The majority of primary CNS tumors arise in the major cortical lobes.
  • Twenty nine percent of primary CNS tumors arise from the dural meninges that encase the CNS structures.
  • The vast majority of these are meningiomas, of which over 90% are benign.
  • About 10% of primary CNS tumors are found in the sella turcica region, where the pituitary gland resides.
  • Other much less common sites of primary CNS tumors include the pineal region, ventricular system, cerebellum, brain stem, cranial nerves, and spinal cord.
  • The distribution of CNS tumors by histology has seen a slight increase in more malignant tumors over the past decade, possibly due to increased neuroimaging practices or environmental exposures.
  • Arising from glial cells, gliomas represent over 36% of all primary CNS tumors and consist of astrocytomas, oligodendrogliomas, ependymomas, mixed gliomas, and neuroepithelial tumors.
  • The benign meningiomas make up 32% of primary CNS tumors, followed by nerve sheath tumors and pituitary tumors.
  • Primary CNS lymphomas, embryonal tumors, and craniopharyngiomas are uncommon.
  • The most common gliomas are astrocytomas, and these tumors are typically classified by the World Health Organization (WHO) as Grades I through IV.
  • We also review the importance of glioma stem cell biology and tumor immunology in early gliomagenesis.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / genetics
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Humans. Neoplastic Stem Cells / metabolism. Prognosis. Risk Factors. Signal Transduction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22112477.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Hattingen E, Blasel S, Nichtweiss M, Zanella FE, Weidauer S: MR imaging of midbrain pathologies. Clin Neuroradiol; 2010 Jun;20(2):81-97
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The spectrum of pathologic processes affecting the midbrain features some differences to other brain areas.
  • Primary midbrain tumors are also infrequent and often show a benign clinical course.
  • Apart from multiple sclerosis other inflammatory autoimmune processes and some infectious agents predominantly affect the brainstem including the midbrain.
  • [MeSH-major] Brain Stem Hemorrhage, Traumatic / diagnosis. Brain Stem Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Mesencephalon / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20532857.001).
  • [ISSN] 1869-1447
  • [Journal-full-title] Clinical neuroradiology
  • [ISO-abbreviation] Clin Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 103
  •  go-up   go-down


28. Barajas RF Jr, Chi J, Guo L, Barbaro N: Microvascular decompression in hemifacial spasm resulting from a cerebellopontine angle lipoma: case report. Neurosurgery; 2008 Oct;63(4):E815-6; discussion E816
Hazardous Substances Data Bank. TEFLON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No attempt was made to resect the lipoma, given the risk to injury of the brainstem and perforating blood vessels.
  • CONCLUSION: This case demonstrates that relief of the vascular compression, when present, of the VIIth cranial nerve is sufficient for resolution of hemifacial spasm symptoms, even when associated with nearby, benign lesions.
  • [MeSH-major] Cerebellar Neoplasms / complications. Cerebellopontine Angle / pathology. Decompression, Surgical / methods. Hemifacial Spasm / etiology. Lipoma / complications. Vascular Surgical Procedures / methods
  • [MeSH-minor] Aged. Cerebral Arteries / pathology. Cerebral Arteries / surgery. Electromyography. Evoked Potentials, Auditory, Brain Stem. Facial Nerve / pathology. Facial Nerve / surgery. Hearing Loss / diagnosis. Hearing Loss / etiology. Humans. Male. Monitoring, Intraoperative. Neurosurgical Procedures / methods. Polytetrafluoroethylene. Prostheses and Implants. Recovery of Function. Vestibulocochlear Nerve / pathology. Vestibulocochlear Nerve / surgery

  • Genetic Alliance. consumer health - Hemifacial Spasm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981850.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / TL1 RR024129-01
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-84-0 / Polytetrafluoroethylene
  •  go-up   go-down


29. Kondziolka D, Flickinger JC, Lunsford LD: The principles of skull base radiosurgery. Neurosurg Focus; 2008;24(5):E11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stereotactic radiosurgery is commonly used for selected patients with benign cranial base tumors.
  • The goal of radiosurgery is cessation of tumor growth and preservation of neurological function.
  • [MeSH-major] Cranial Irradiation / methods. Radiosurgery / methods. Skull Base Neoplasms / surgery
  • [MeSH-minor] Brain Stem / physiopathology. Brain Stem / surgery. Cerebellar Neoplasms / surgery. Cerebellopontine Angle / surgery. Cranial Nerve Injuries / prevention & control. Decompression, Surgical. Diagnostic Imaging. Humans. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Patient Selection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447740.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


30. Surash S, Ismail A, Loughrey C, van Hille P: Malignant transformation of a neurenteric cyst in the posterior fossa following complete excision. Br J Neurosurg; 2009 Aug;23(4):458-61
MedlinePlus Health Information. consumer health - Neural Tube Defects.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He re-presented with non-specific symptoms and hydrocephalus, and subsequent evidence of a complex lesion surrounding the lower brain stem and upper cervical cord.
  • Histologically the original lesion was a benign neurenteric cyst, whereas the recurrent lesion showed a well differentiated adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Cerebellar Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neural Tube Defects / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637023.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. Vesper J, Bölke B, Wille C, Gerber PA, Matuschek C, Peiper M, Steiger HJ, Budach W, Lammering G: Current concepts in stereotactic radiosurgery - a neurosurgical and radiooncological point of view. Eur J Med Res; 2009 Mar 17;14(3):93-101
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gamma knife and the stereotactically modified linear accelerator (LINAC) are radiosurgical equipments to treat predetermined intracranial targets through the intact skull without damaging the surrounding normal brain tissue.
  • The impact of radiosurgery is presented for the management of gliomas, metastases, brain stem lesions, benign tumours and vascular malformations and selected functional disorders such as trigeminal neuralgia.
  • [MeSH-major] Brain Diseases / surgery. Radiosurgery / methods
  • [MeSH-minor] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Brain Stem / pathology. Brain Stem / surgery. Central Nervous System Vascular Malformations / surgery. Humans. Neurosurgery. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):681-6 [15542976.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1515-9 [15590183.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):197-204 [11856595.001]
  • [Cites] Epilepsia. 2002 Mar;43(3):292-300 [11906515.001]
  • [Cites] Stereotact Funct Neurosurg. 2001;76(1):29-35 [12007276.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):65-72 [12134934.001]
  • [Cites] Radiother Oncol. 2002 Jun;63(3):347-54 [12142099.001]
  • [Cites] Phys Med Biol. 2002 Jul 21;47(14):2471-94 [12171335.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):347-53 [12186463.001]
  • [Cites] Acta Neurochir Suppl. 2002;84:57-63 [12379005.001]
  • [Cites] Neurosurgery. 2003 Jan;52(1):140-6; discussion 146-7 [12493111.001]
  • [Cites] Phys Med Biol. 2003 Jan 21;48(2):211-21 [12587905.001]
  • [Cites] Oncology (Williston Park). 1993 Sep;7(9):93-100; discussion 103, 106 [8217533.001]
  • [Cites] Clin Neurosurg. 1993;40:475-97 [8111997.001]
  • [Cites] Acta Neurochir (Wien). 1994;129(1-2):92-6 [7998504.001]
  • [Cites] Acta Neurochir Suppl. 1995;63:20-4 [7502722.001]
  • [Cites] Acta Neurochir Suppl. 1995;63:29-34 [7502724.001]
  • [Cites] Acta Neurochir Suppl. 1995;63:57-9 [7502730.001]
  • [Cites] Br J Neurosurg. 1995;9(5):593-603 [8561931.001]
  • [Cites] Stereotact Funct Neurosurg. 1995;64 Suppl 1:118-25 [8584819.001]
  • [Cites] Stereotact Funct Neurosurg. 1995;64 Suppl 1:147-54 [8584822.001]
  • [Cites] Stereotact Funct Neurosurg. 1995;64(2):57-100 [8602454.001]
  • [Cites] J Neurooncol. 1997 Jul;33(3):213-21 [9195493.001]
  • [Cites] Acta Neurochir Suppl. 1997;68:118-23 [9233426.001]
  • [Cites] J Neurosurg. 2008 Aug;109(2):191-8 [18671629.001]
  • [Cites] Neurosurg Focus. 2008 Sep;25(3):E8 [18759632.001]
  • [Cites] Eur J Med Res. 2009 Mar 17;14(3):102-5 [19380279.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41 [10613305.001]
  • [Cites] Stereotact Funct Neurosurg. 1999;72 Suppl 1:29-37 [10681688.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):576-82; discussion 582-3 [10719853.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1371-80 [10780513.001]
  • [Cites] Stereotact Funct Neurosurg. 1999;72(2-4):77-81 [10853056.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):817-24 [11020579.001]
  • [Cites] J Neurol. 2000 Sep;247 Suppl 4:IV/2-7 [11199811.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:113-9 [11143227.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Feb;127(2):91-5 [11216919.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):285-94; discussion 294-6 [11220370.001]
  • [Cites] Stereotact Funct Neurosurg. 2000;74(3-4):179-84 [11279358.001]
  • [Cites] Stereotact Funct Neurosurg. 2000;74(3-4):185-93 [11279359.001]
  • [Cites] Technol Cancer Res Treat. 2003 Apr;2(2):127-34 [12680793.001]
  • [Cites] J Neurosurg. 2003 Apr;98(4):920-5 [12691424.001]
  • [Cites] Strahlenther Onkol. 2003 Apr;179(4):219-32 [12707711.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Childs Nerv Syst. 2003 Jun;19(5-6):305-10 [12732939.001]
  • [Cites] Stereotact Funct Neurosurg. 2002;79(3-4):202-13 [12890978.001]
  • [Cites] Neurosurgery. 2003 Oct;53(4):815-21; discussion 821-2 [14519213.001]
  • [Cites] Neurosurgery. 2003 Oct;53(4):823-8; discussion 828-30 [14519214.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:45-50 [14531560.001]
  • [Cites] Cancer Treat Rev. 2003 Dec;29(6):533-40 [14585263.001]
  • [Cites] Phys Med Biol. 2003 Dec 21;48(24):4105-10 [14727754.001]
  • [Cites] Hawaii Dent J. 2003 Nov-Dec;34(6):14-5 [14964081.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):112-6 [15093906.001]
  • [Cites] Strahlenther Onkol. 2004 Jul;180(7):401-7 [15241527.001]
  • [Cites] Neurosurg Clin N Am. 2004 Jul;15(3):319-34 [15246340.001]
  • [Cites] Am J Clin Oncol. 2004 Aug;27(4):420-4 [15289738.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Aug;47(4):238-41 [15346322.001]
  • [Cites] J Neurosurg. 2004 Oct;101(4):590-3 [15481711.001]
  • [Cites] Appl Neurophysiol. 1980;43(3-5):189-97 [7027938.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1988;42:193-7 [3055830.001]
  • [Cites] Cancer. 1990 Feb 1;65(3 Suppl):792-9 [2154318.001]
  • [Cites] Curr Opin Oncol. 1990 Aug;2(4):673-8 [2095876.001]
  • [Cites] J Neurosurg. 1992 Mar;76(3):444-9 [1738025.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1991;52:75-7 [1792973.001]
  • [Cites] Acta Neurochir (Wien). 1992;116(1):14-22 [1615765.001]
  • [Cites] Neurosurg Clin N Am. 1990 Jan;1(1):161-72 [2135965.001]
  • [Cites] N C Med J. 1992 Aug;53(8):395-9 [1513382.001]
  • [Cites] Acta Neurochir (Wien). 1992;119(1-4):53-61 [1481753.001]
  • [Cites] Acta Neurochir (Wien). 1993;121(1-2):82-5 [8475813.001]
  • [Cites] Curr Opin Oncol. 1993 May;5(3):464-73 [8494907.001]
  • [Cites] Cancer Treat Rev. 1993 Jul;19(3):261-81 [8392909.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):353-61 [8407410.001]
  • [Cites] Neurosurgery. 1998 May;42(5):996-1002; discussion 1002-4 [9588543.001]
  • [Cites] Neurol Res. 1998 Sep;20(6):479-92 [9713837.001]
  • [Cites] Forum (Genova). 1998 Jul-Sep;8(3):272-81 [9755292.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:192-9 [9782251.001]
  • [Cites] Arch Neurol. 1998 Dec;55(12):1524-9 [9865796.001]
  • [Cites] Neurosurgery. 1999 Jan;44(1):12-20; discussion 20-2 [9894959.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):321-7 [10030256.001]
  • [Cites] Med Phys. 1999 Feb;26(2):166-70 [10076969.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):157-61 [10328588.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):485-95 [8823776.001]
  • [Cites] Br J Neurosurg. 1996 Apr;10(2):169-74 [8861308.001]
  • [Cites] J Neurosurg. 1999 Oct;91(4):563-8 [10507375.001]
  • [Cites] Acta Chir Scand. 1951 Dec 13;102(4):316-9 [14914373.001]
  • [Cites] Surg Neurol. 2004 Nov;62(5):435-44; discussion 444-6 [15518853.001]
  • [Cites] Tecnologica. 1995 Aug;:9-10 [10168296.001]
  • [Cites] Neurol Clin. 1998 Feb;16(1):35-54 [9421540.001]
  • [Cites] Radiologe. 1997 Dec;37(12):995-1002 [9498251.001]
  • [Cites] Oncology (Williston Park). 1998 Apr;12(4):537-43, 547; discussion 547-8, 553 [9575527.001]
  • [Cites] J Neurovirol. 1998 Apr;4(2):227-36 [9584959.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E11 [18447740.001]
  • [Cites] J Natl Compr Canc Netw. 2008 May;6(5):505-13; quiz 514 [18492462.001]
  • [Cites] Acta Oncol. 2008;47(5):917-27 [17957500.001]
  • [Cites] Neurosurgery. 2008 May;62(5 Suppl):A29-36; discussion A36 [18580778.001]
  • [Cites] Neurosurgery. 2008 May;62(5 Suppl):A44-52; discussion A52 [18580780.001]
  • [Cites] Acta Neurochir Suppl. 2008;101:35-8 [18642631.001]
  • [Cites] Neurology. 2008 Jul 22;71(4):277-82 [18645166.001]
  • [Cites] Lancet Neurol. 2005 Jan;4(1):4-5 [15620846.001]
  • [Cites] Z Med Phys. 2004;14(4):222-9 [15656104.001]
  • [Cites] Neurosurg Focus. 2003 May 15;14(5):e6 [15669817.001]
  • [Cites] Neurosurgery. 2005 Feb;56(2):257-65; discussion 257-65 [15670374.001]
  • [Cites] Acta Neurochir Suppl. 2004;91:1-7 [15707021.001]
  • [Cites] Acta Neurochir Suppl. 2004;91:25-32 [15707023.001]
  • [Cites] Stereotact Funct Neurosurg. 2004;82(5-6):244-9 [15637446.001]
  • [Cites] J Appl Clin Med Phys. 2004 Spring;5(2):18-28 [15738910.001]
  • [Cites] Lancet Neurol. 2005 May;4(5):289-98 [15847842.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):246-52 [15850928.001]
  • [Cites] Neurosurgery. 2005 Jun;56(6):1295-301; discussion 1301-3 [15918946.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):47-55 [16111571.001]
  • [Cites] Minim Invasive Neurosurg. 2005 Oct;48(5):310-4 [16320196.001]
  • [Cites] Stereotact Funct Neurosurg. 2005;83(5-6):228-32 [16534255.001]
  • [Cites] Neurol Res. 2006 Apr;28(3):320-5 [16687060.001]
  • [Cites] J Neurosurg. 2006 Jun;104(6):913-24 [16776335.001]
  • [Cites] Prog Neurol Surg. 2006;19:152-70 [17033153.001]
  • [Cites] Radiother Oncol. 2006 Oct;81(1):25-32 [17005278.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1):8-17 [17236482.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):521-4 [17097830.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):287-94 [17031558.001]
  • [Cites] Prog Neurol Surg. 2007;20:129-41 [17317981.001]
  • [Cites] Med Phys. 2007 Apr;34(4):1487-95 [17500479.001]
  • [Cites] Technol Cancer Res Treat. 2007 Jun;6(3):169-76 [17535024.001]
  • [Cites] Otolaryngol Clin North Am. 2007 Jun;40(3):571-88, ix [17544696.001]
  • [Cites] Neurosurg Focus. 2007;22(3):E3 [17608356.001]
  • [Cites] Oncologist. 2007 Jul;12(7):884-98 [17673619.001]
  • [Cites] J Neurosurg Spine. 2007 Aug;7(2):151-60 [17688054.001]
  • [Cites] J Neurosurg. 2007 Aug;107(2):325-36 [17695387.001]
  • [Cites] Epilepsy Res. 2007 Aug;76(1):15-21 [17643965.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E5 [17961042.001]
  • [Cites] J Neurooncol. 2008 Jan;86(2):195-205 [17628747.001]
  • [Cites] Neurosurg Focus. 2007;23(6):E3 [18081480.001]
  • [Cites] Neurosurg Focus. 2007;23(6):E7 [18081484.001]
  • [Cites] Neurosurg Focus. 2007;23(6):E8 [18081485.001]
  • [Cites] Clin Adv Hematol Oncol. 2007 Nov;5(11):894-902, 907-15 [18185489.001]
  • [Cites] Arch Neurol. 2008 Feb;65(2):177-83 [18268185.001]
  • [Cites] Semin Oncol. 2008 Apr;35(2):100-7 [18396195.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008;71(1 Suppl):S131-5 [18406912.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):170-80 [11285555.001]
  • [Cites] Front Radiat Ther Oncol. 2001;35:30-47 [11351951.001]
  • [Cites] Med Phys. 2001 Sep;28(9):1839-41 [11585214.001]
  • [Cites] Clin Neurosurg. 2001;48:96-110 [11692659.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Dec;15(6):1027-52 [11770297.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):199-205 [11780888.001]
  • [Cites] Clin J Pain. 2002 Jan-Feb;18(1):42-7 [11803302.001]
  • [Cites] Neurosurgery. 2002 Mar;50(3):494-500; discussion 500-2 [11841716.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):143-9 [12622453.001]
  • [Cites] Technol Cancer Res Treat. 2003 Apr;2(2):105-10 [12680790.001]
  • [Cites] Br J Neurosurg. 1996 Apr;10(2):229 [8861320.001]
  • [Cites] Neurosurgery. 1996 Feb;38(2):318-24 [8869059.001]
  • [Cites] Neurosurg Clin N Am. 1997 Jan;8(1):75-8 [9018707.001]
  • (PMID = 19380278.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 154
  • [Other-IDs] NLM/ PMC3352064
  •  go-up   go-down


35. Cultrera F, Guiducci G, Nasi MT, Paioli G, Frattarelli M: Two-stage treatment of a tectal ganglioglioma: endoscopic third ventriculostomy followed by surgical resection. J Clin Neurosci; 2006 Nov;13(9):963-5
MedlinePlus Health Information. consumer health - Hydrocephalus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumours of the quadrigeminal plate in adults are usually benign.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Ganglioglioma / surgery. Hydrocephalus / surgery. Tectum Mesencephali / surgery. Third Ventricle / surgery. Ventriculostomy / methods

  • Genetic Alliance. consumer health - Ganglioglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16914316.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


36. Matsuno A, Nagashima H, Ishii H, Iwamuro H, Nagashima T: Aggressive and invasive growth of tectal glioma after surgical intervention and chemoradiotherapy. Br J Neurosurg; 2006 Aug;20(4):246-9
MedlinePlus Health Information. consumer health - Hydrocephalus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A tectal glioma presenting with late-onset aqueduct stenosis and obstructive hydrocephalus is usually categorized as a benign glioma.
  • [MeSH-major] Brain Neoplasms / therapy. Brain Stem. Glioma / therapy. Hydrocephalus / therapy. Ventriculostomy / methods
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / methods. Cranial Irradiation. Endoscopy / methods. Female. Humans. Magnetic Resonance Imaging / methods. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954079.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Vougioukas VI, Gläsker S, Hubbe U, Berlis A, Omran H, Neumann HP, Van Velthoven V: Surgical treatment of hemangioblastomas of the central nervous system in pediatric patients. Childs Nerv Syst; 2006 Sep;22(9):1149-53
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Hemangioblastomas are histologically benign lesions that occur sporadically or as a manifestation of von Hippel-Lindau disease (VHL).
  • The treatment strategy of these neoplasms is complicated by their unpredictable growth patterns and the often irreversible neurological deficits they may cause.
  • Ten patients were affected by von Hippel-Lindau and three were with sporadic tumors.
  • Two patients with brainstem tumors exhibited transient hemiparesis and caudal nerve palsy, respectively.
  • Preoperatively symptomatic patients with spinal tumors did not deteriorate nor improve after surgery.
  • During the observed follow-up periods, no tumor recurrences were observed.
  • Molecular screening of every pediatric patient and family is mandatory to enable the detection of extraneurological tumors and the development of an efficient therapeutic strategy.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Cerebellar Neoplasms / surgery. Hemangioblastoma / surgery. Spinal Cord Neoplasms / surgery. von Hippel-Lindau Disease / surgery
  • [MeSH-minor] Adolescent. Brain Stem / pathology. Brain Stem / surgery. Cerebellum / pathology. Cerebellum / surgery. Child. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neurologic Examination. Postoperative Complications / diagnosis. Spinal Cord / pathology. Spinal Cord / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16369852.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


38. Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W 3rd, Tonsgard JH, Welling DB, Widemann B, Yohay K: Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res; 2009 Aug 15;15(16):5032-5039
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder associated primarily with bilateral schwannomas seen on the superior vestibular branches of the eighth cranial nerves.
  • Significant morbidity can result from surgical treatment of these tumors.
  • Meningiomas, ependymomas, and other benign central nervous system tumors are also common in NF2.
  • [MeSH-minor] Animals. Auditory Brain Stem Implants. Cochlear Implants. Drug Evaluation, Preclinical / methods. Drug Evaluation, Preclinical / trends. Humans. Meningeal Neoplasms / therapy. Meningioma / therapy. Time Factors

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2002 Mar;20(3):475-82 [11836557.001]
  • [Cites] Curr Biol. 2006 Apr 4;16(7):702-9 [16581517.001]
  • [Cites] J Med Genet. 2007 Jul;44(7):424-8 [17307835.001]
  • [Cites] Hum Gene Ther. 2006 Jan;17(1):20-30 [16409122.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] J Med Genet. 2008 Jun;45(6):332-9 [18285426.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] Brain Pathol. 2008 Jan;18(1):62-70 [17924978.001]
  • [Cites] Laryngoscope. 2007 Jun;117(6):1069-72 [17545869.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):27-36 [16341207.001]
  • [Cites] Genes Dev. 2005 Oct 1;19(19):2265-77 [16204178.001]
  • [Cites] Neoplasia. 2002 Nov-Dec;4(6):501-9 [12407444.001]
  • [Cites] Oncogene. 2009 Feb 12;28(6):854-65 [19029950.001]
  • [Cites] J Med Genet. 1992 Dec;29(12 ):841-6 [1479598.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):978-86 [10215625.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] Otol Neurotol. 2005 Jul;26(4):733-40 [16015177.001]
  • [Cites] Otol Neurotol. 2008 Jan;29(1):58-68 [18199958.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):994-1003 [11589430.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):93-7 [15699726.001]
  • [Cites] J Neurosurg. 2002 Jun;96(6):1063-71 [12066908.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):715-23 [12235555.001]
  • [Cites] Neurology. 2002 Dec 10;59(11):1759-65 [12473765.001]
  • [Cites] Am J Otol. 1998 Sep;19(5):638-43 [9752973.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] Neurosurgery. 2008 Jun;62(6):1314-9; discussion 1319-20 [18824998.001]
  • [Cites] Neurology. 2007 Feb 27;68(9):643-7 [17215493.001]
  • [Cites] Br J Cancer. 2007 Sep 3;97(5):577-81 [17726450.001]
  • [Cites] Stat Med. 1999 Aug 15;18(15):1905-42 [10532877.001]
  • [Cites] Am J Hum Genet. 2007 Apr;80(4):805-10 [17357086.001]
  • [Cites] Neurology. 2000 Jan 11;54(1):71-6 [10636128.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):5-12 [16147576.001]
  • [Cites] J Cell Biol. 2007 Jun 4;177(5):893-903 [17548515.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 19671848.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / K08 DC009288
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Number-of-references] 36
  • [Other-IDs] NLM/ NIHMS707923; NLM/ PMC4513640
  •  go-up   go-down


39. Gokce M: Analysis of isolated cranial nerve manifestations in patients with cancer. J Clin Neurosci; 2005 Nov;12(8):882-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They included meningeal carcinomatosis (10/16), brain stem metastases (3/16), primary brain astrocytomas (1/16), and metastases out of the central nervous system (2/16).
  • Although most of the isolated CN manifestations were due to systemic metastasis, in particular to the meninges, up to 20% were related to benign conditions.
  • [MeSH-major] Cranial Nerve Diseases / etiology. Neoplasms / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Meningeal Neoplasms / secondary. Middle Aged. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16326269.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


40. Ternier J, Wray A, Puget S, Bodaert N, Zerah M, Sainte-Rose C: Tectal plate lesions in children. J Neurosurg; 2006 Jun;104(6 Suppl):369-76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: The authors characterized the clinical course of tectal plate lesions in a group of pediatric patients to identify the prognostic factors at presentation that predict progression, in an attempt to differentiate tectal hamartomas from tumors.
  • Fourteen children whose tumors demonstrated radiological progression (enlargement, contrast enhancement, or cystic change) were treated surgically.
  • Histologically, 80% of the surgically treated lesions were low grade (with the other 20% consisting of one dysplasia, one high-grade tumor, and one unidentified tumor).
  • The only factor predictive of tumor enlargement was lesion volume at presentation (p = 0.002).
  • Lesions with a volume less than 4 cm3 were likely to be hamartomas and followed a predominantly benign course, with few atypical cases progressing.
  • All large lesions, defined as having a volume greater than 10 cm3 at presentation, eventually required treatment, and all were histologically determined to be tumors.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / surgery. Glioma / pathology. Glioma / surgery. Tectum Mesencephali

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16776370.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Elmalem VI, Younge BR, Biousse V, Leavitt JA, Moster ML, Warner J, Kupersmith MJ, Landau K, Brodsky MC, Frohman LP, May EF, Tomsak RL, Newman NJ: Clinical course and prognosis of trochlear nerve schwannomas. Ophthalmology; 2009 Oct;116(10):2011-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inclusion criteria were brain magnetic resonance imaging (MRI) with a lesion suggestive of a schwannoma along the course of the fourth nerve.
  • Exclusion criteria were other causes of fourth nerve palsy, such as congenital, traumatic or microvascular; normal (or lack of) initial brain MRI; lack of adequate clinical information; and disappearance of the lesion on subsequent follow-up brain MRI.
  • CONCLUSIONS: Patients with isolated fourth nerve palsy and small lesions of the fourth nerve have a good prognosis and should be followed with serial MRI scans without neurosurgical intervention unless they develop signs of brain stem compression.
  • Most patients with diplopia and benign fourth nerve lesions typical of trochlear nerve schwannoma can adapt with either prism spectacles or no treatment at all, although strabismus surgery can be successful.
  • [MeSH-major] Cranial Nerve Neoplasms / pathology. Neurilemmoma / pathology. Trochlear Nerve Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19699532.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / P30-EY06360
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR: Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol; 2010;8:147
Hazardous Substances Data Bank. AZACITIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent data provide significant evidence to support the hypothesis that there are sub-populations of cells within solid tumors that have an increased tumor initiating potential relative to the total tumor population.
  • CD133, a cell surface marker expressed on primitive cells of neural, hematopoietic, endothelial and epithelial lineages has been identified as a marker for tumor initiating cells in solid tumors of the brain, colon, pancreas, ovary and endometrium.
  • Our objectives were to assess the relative level of CD133 expressing cells in primary human endometrial tumors, confirm their tumorigenic potential, and determine whether CD133 expression was epigenetically modified.
  • METHODS: We assessed CD133 expression in primary human endometrial tumors by flow cytometry and analyzed the relative tumorigenicity of CD133+ and CD133- cells in an in vivo NOD/SCID mouse model.
  • We further examined CD133 promoter methylation and expression in normal endometrium and malignant tumors.
  • In addition, we confirmed the tumor initiating potential of CD133+ and CD133- cell fractions in NOD/SCID mice.
  • Interestingly, the percentage of CD133+ cells in human endometrial tumor xenografts, as evidenced by immunofluorescence, increased with serial transplantation although this trend was not consistently detected by flow cytometry.
  • To support this finding, we demonstrated that regions of the CD133 promoter were hypomethylated in malignant endometrial tissue relative to benign control endometrial tissue.
  • Lastly, we determined that methylation of the CD133 promoter decreases over serial transplantation of an endometrial tumor xenograft.
  • [MeSH-major] Antigens, CD / genetics. Cell Transformation, Neoplastic / pathology. Endometrial Neoplasms / pathology. Epigenomics. Glycoproteins / genetics. Neoplastic Stem Cells / pathology. Peptides / genetics
  • [MeSH-minor] Animals. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Female. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 2008 Oct;18(10):1037-46 [18679414.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8094-103 [18829568.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Cancer Lett. 2009 Jun 28;279(1):13-21 [19232461.001]
  • [Cites] Biol Reprod. 2009 Jun;80(6):1136-45 [19228591.001]
  • [Cites] Anticancer Res. 2009 Jun;29(6):2235-7 [19528487.001]
  • [Cites] Clin Cancer Res. 2009 Jul 1;15(13):4299-311 [19509143.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] BMC Cancer. 2009;9:221 [19583859.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8241-8 [19843861.001]
  • [Cites] Stem Cells. 2009 Oct;27(10):2405-13 [19658191.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] J Biochem. 2010 Sep;148(3):273-80 [20551139.001]
  • [Cites] Hum Pathol. 2010 Nov;41(11):1516-29 [20800872.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Endocr Relat Cancer. 2000 Dec;7(4):227-42 [11174845.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R1-8 [12559051.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2055-61 [14630820.001]
  • [Cites] Biol Reprod. 2004 Jun;70(6):1738-50 [14766732.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Biol Reprod. 1989 Mar;40(3):681-90 [2758097.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5002-12 [9389720.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5013-21 [9389721.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1529-38 [16456137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Hum Reprod. 2007 Jan;22(1):45-51 [16923745.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Hum Reprod. 2007 May;22(5):1214-23 [17283036.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):479-85 [17762575.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):242-9 [18256549.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):506-14 [17868344.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] J Mol Med (Berl). 2008 Sep;86(9):1025-32 [18535813.001]
  • [Cites] Oncogene. 2009 Jan 15;28(2):209-18 [18836486.001]
  • (PMID = 21122138.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC3027593
  •  go-up   go-down


43. Tchoghandjian A, Fernandez C, Colin C, El Ayachi I, Voutsinos-Porche B, Fina F, Scavarda D, Piercecchi-Marti MD, Intagliata D, Ouafik L, Fraslon-Vanhulle C, Figarella-Branger D: Pilocytic astrocytoma of the optic pathway: a tumour deriving from radial glia cells with a specific gene signature. Brain; 2009 Jun;132(Pt 6):1523-35
Genetic Alliance. consumer health - Pilocytic astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These tumours affect preferentially the cerebellum (benign clinical course) and the optic pathway, especially the hypothalamo-chiasmatic region (poor prognosis).
  • [MeSH-major] Astrocytoma / diagnosis. Optic Nerve Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Astrocytes / metabolism. Cell Proliferation. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / genetics. Cerebellar Neoplasms / pathology. Child. Child, Preschool. DNA, Neoplasm / genetics. Diagnosis, Differential. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Hypothalamus / metabolism. Infant. Middle Aged. Neoplastic Stem Cells / pathology. Neuroglia / pathology. Oligonucleotide Array Sequence Analysis / methods. Optic Chiasm / cytology. Optic Chiasm / embryology. Optic Chiasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Up-Regulation. Vimentin / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336457.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Vimentin
  •  go-up   go-down


44. Katoh M, Imamura H, Yoshino M, Aoki T, Abumiya T, Aida T: Spontaneous regression of an anterior skull base mass. J Clin Neurosci; 2010 Jun;17(6):786-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient attended our outpatient department approximately once per month for a regular check-up following a brain stem infarction.
  • Although the definition does include some types of malignant lesion, most masses are benign lesions that can regress spontaneously, as in our patient.
  • [MeSH-major] Neoplasm Regression, Spontaneous. Skull Base / pathology. Skull Base Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20356749.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


45. Colin C, Baeza N, Tong S, Bouvier C, Quilichini B, Durbec P, Figarella-Branger D: In vitro identification and functional characterization of glial precursor cells in human gliomas. Neuropathol Appl Neurobiol; 2006 Apr;32(2):189-202
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, pilocytic astrocytomas contain slowly dividing oligodendrocyte-type2-astrocyte/oligodendrocyte precursor cells in keeping with their benign behaviour whereas both glioblastomas and oligodendrogliomas contain neoplastic glial restricted precursor cells.
  • [MeSH-major] Brain Neoplasms / physiopathology. Glioma / pathology. Neuroglia / cytology. Stem Cells / cytology


46. Temprano T, Fernández-de León R, Rial JC, Fernández JM, Mateos V: [Cystic bulbar hemangioblastoma]. Rev Neurol; 2008 Aug 1-15;47(3):134-6
Genetic Alliance. consumer health - Hemangioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Hemangioblastomas are neoplasm of vascular type having benign characteristics.
  • They represent between 2-3% of brain tumors and 7-12% of neoformative processes in the posterior fossa.
  • Brain tumor was diagnosed by neuroimage techniques.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Hemangioblastoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18654967.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


47. Rivero-Celada D, Carcavilla-Loncán LI, Marín-Cárdenas MA, Cantero-Antón JM, Alfaro-Torres J, Duato-Jané F, Eiras-Ajuria J: [Tumoral degeneration occurring over a non-healing meningocele. Report of two cases]. Neurocirugia (Astur); 2006 Dec;17(6):532-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A giant meningocelic sac has not been usually described in adult patients, due to the fact that it shows a low incidence and few newborn have survived to date though the malformation is benign.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Meningeal Neoplasms / etiology. Meningioma / etiology. Meningocele / complications. Sarcoma / etiology. Teratocarcinoma / etiology
  • [MeSH-minor] Aged. Brain Neoplasms / secondary. Cell Transformation, Neoplastic. Epidermal Cyst / etiology. Epidermal Cyst / pathology. Fatal Outcome. Female. Humans. Incidental Findings. Ischemia / etiology. Lumbar Vertebrae / abnormalities. Male. Middle Aged. Multipotent Stem Cells / pathology. Paraplegia / etiology. Sacrum / abnormalities. Spinal Cord / blood supply. Spinal Dysraphism / complications

  • Genetic Alliance. consumer health - Meningocele.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17242841.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 21
  •  go-up   go-down


48. Kovács T, Osztie E, Bodrogi L, Pajor P, Farsang M, Juhász C, Szirmai I: Cerebellar developmental venous anomalies with associated vascular pathology. Br J Neurosurg; 2007 Apr;21(2):217-23
MedlinePlus Health Information. consumer health - Cerebellar Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cerebellar developmental venous anomalies (CDVA) are benign conditions, although sometimes they are associated with haemorrhages and reported to be symptomatic.
  • One patient had two CDVAs, while another had a unique draining vein from the upper part of the brainstem too.
  • In conclusion, CDVAs are benign, asymptomatic conditions, but they are sometimes associated with pathogenic malformations requiring detailed neuroradiological investigations.
  • [MeSH-minor] Adult. Brain Stem Neoplasms / complications. Brain Stem Neoplasms / pathology. Female. Follow-Up Studies. Hemangioma, Cavernous / complications. Hemangioma, Cavernous / pathology. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453792.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Géhanne C, Delpierre I, Damry N, Devroede B, Brihaye P, Christophe C: Skull base chordoma: CT and MRI features. JBR-BTR; 2005 Nov-Dec;88(6):325-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lesion of the body of the clivus can extend ventrally or dorsally and cause cranial nerve palsies, brain stem compression or hydrocephalus.
  • Pathologically, they form soft, grey masses that are histologically benign but locally invasive and destructive.
  • [MeSH-major] Chordoma / diagnosis. Magnetic Resonance Imaging. Skull Base Neoplasms / diagnosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Chordoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440571.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


50. Fukaya R, Yoshida K, Ohira T, Kawase T: Trigeminal schwannomas: experience with 57 cases and a review of the literature. Neurosurg Rev; 2010 Apr;34(2):159-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trigeminal schwannoma is a mostly benign tumor that can be cured by complete resection.
  • Over the last few decades, several pioneers have developed surgical approaches enabling the total removal of such tumors.
  • Since 1990, all such patients have been treated using three main types of middle fossa skull base approaches, which minimize the exposure of the brain: the anterior transpetrosal approach, subtemporal interdural approach (Dolenc), or a combination of these approaches.
  • Before 1990, total tumor removal was achieved in only three of eight patients (38%).
  • After 1990, the tumors were totally removed in 43 patients (90%) and were nearly completely removed in an additional three patients (6%).
  • However, total surgical removal after surgery and Gamma knife surgery was very difficult because of dense adhesions to the brain stem and cranial nerves.
  • A correct anatomical knowledge is critical for minimizing brain exposure and avoiding surgical complications.
  • [MeSH-major] Cranial Nerve Neoplasms / surgery. Neurilemmoma / surgery. Trigeminal Nerve Diseases / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cranial Fossa, Middle / surgery. Dura Mater / surgery. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Male. Middle Aged. Neoplasm Recurrence, Local. Neurosurgical Procedures / methods. Radiosurgery. Retrospective Studies. Skull Base / surgery. Temporal Bone / surgery. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20963463.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Zhou J, Li NY, Zhou XJ, Zhou HB, Wu B, Jiang SJ, Ma HH, Zhang RS: [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system]. Zhonghua Bing Li Xue Za Zhi; 2010 Mar;39(3):145-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 10 patients presenting other lesions related to VHL, including 6 retinal HBs, 4 pancreatic tumors (endocrine tumor and microcystic cystadenoma), 1 clear renal cell carcinoma, 4 renal cysts and 1 endolymphatic sac tumor.
  • One patient developed 5 different tumors related to VHL within a period of 4 years.
  • Histologically, the tumors showed large and vacuolated stromal cells.
  • Some tumors showed atypical nuclei.
  • Involvement of the brain tissue was seen in 32 cases, among which, 21 patients with available follow-up information were learnt to be alive.
  • Tumor cells of HB stained positive for vimentin, EGFR, Inhibin alpha and D2-40, but negative for CD34 and CD68.
  • CONCLUSIONS: VHL syndrome is a multisystem disorder with a poor prognosis and a high rate of missed diagnosis.
  • The syndrome is characterized by development of various benign and malignant tumors.
  • The most common tumor is CNS-HB, which occurs predominantly in the cerebellum.
  • Patients with VHL syndrome tend to present at a younger age than patients with sporadic CNS-HBs, and VHL related HB occurs more predominantly in the brain stem and spinal cord.
  • Prognosis of CNS-HB patients is not correlated with the nuclear atypicality, expression for Ki-67 and involvement of the brain tissue.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Hemangioblastoma / pathology. von Hippel-Lindau Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Child. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / metabolism. Humans. Inhibins / metabolism. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Receptor, Epidermal Growth Factor / metabolism. Retinal Neoplasms / metabolism. Retinal Neoplasms / pathology. Retinal Neoplasms / surgery. Survival Analysis. Vimentin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Von Hippel-Lindau syndrome.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450758.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Vimentin; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


52. Beseoglu K, Knobbe CB, Reifenberger G, Steiger HJ, Stummer W: Supratentorial meningeal melanocytoma mimicking a convexity meningioma. Acta Neurochir (Wien); 2006 Apr;148(4):485-90
MedlinePlus Health Information. consumer health - Moles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE AND IMPORTANCE: Meningeal melanocytomas are rare benign neuro-ectodermal tumors arising from melanocytic cells in the leptomeninges.
  • These leptomeningeal melanocytes are found at highest density underneath the brain stem and along the upper cervical spinal cord.
  • INTERVENTION: Tumor control to date was achieved by surgery of the large lesion and radiosurgery of the small lesion.
  • CONCLUSION: Complete tumor resection may be advantageous and second or recurrent lesions may be managed by repeat surgery or stereotactic radiosurgery.
  • [MeSH-major] Melanocytes / pathology. Meningeal Neoplasms / pathology. Meningioma / diagnosis. Neoplasms, Multiple Primary / pathology. Nevus / pathology. Supratentorial Neoplasms / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391879.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down






Advertisement